

El-Hibri Fuad  
Form 4  
September 14, 2009

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
El-Hibri Fuad

2. Issuer Name and Ticker or Trading Symbol  
Emergent BioSolutions Inc. [EBS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
2273 RESEARCH BLVD, SUITE 400

3. Date of Earliest Transaction (Month/Day/Year)  
09/10/2009

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
CEO & Chairman

(Street)  
ROCKVILLE, MD 20850

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 09/10/2009                           |  | M                              |   | 47,600  | A  | \$ 3.5  |
|                                 |                                      |  |                                |   |   |  | 985,019   |
| Common Stock                    | 09/10/2009                           |  | S <sup>(1)</sup>               |   | 47,600  | D  | \$ 19.36  |
|                                 |                                      |  |                                |   |   |  | 937,419   |
| Common Stock                    | 09/11/2009                           |  | M                              |   | 27,900  | A  | \$ 3.5  |
|                                 |                                      |  |                                |   |   |  | 965,319   |
| Common Stock                    | 09/11/2009                           |  | S <sup>(1)</sup>               |   | 27,900  | D  | \$ 19.35  |
|                                 |                                      |  |                                |   |   |  | 937,419   |
|                                 |                                      |  |                                |   |   |  | 5,011 <sup>(4)</sup>                                  |

Edgar Filing: El-Hibri Fuad - Form 4

|              |  |  |  |                          |   |                         |
|--------------|--|--|--|--------------------------|---|-------------------------|
| Common Stock |  |  |  |                          |   | By Karim El-Hibri Trust |
| Common Stock |  |  |  | 5,011 <sup>(4)</sup>     | I | By Yusra El-Hibri Trust |
| Common Stock |  |  |  | 5,011 <sup>(4)</sup>     | I | By Faiza El-Hibri Trust |
| Common Stock |  |  |  | 7,181,835 <sup>(5)</sup> | I | By Intervac, L.L.C.     |
| Common Stock |  |  |  | 2,965,043 <sup>(6)</sup> | I | By BioPharm, L.L.C.     |
| Common Stock |  |  |  | 1,599,155 <sup>(7)</sup> | I | By Biovac, L.L.C.       |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Employee Stock Option (right to buy)       | \$ 3.5   | 09/10/2009                           |  | M                              | 47,600  | 01/01/2008 05/25/2010                                    | Common Stock 47,600   |
| Employee Stock Option (right to            | \$ 3.5   | 09/11/2009                           |  | M                              | 27,900  | 01/01/2008 05/25/2010                                    | Common Stock 27,900   |

buy)

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                |       |
|---|---------------|-----------|----------------|-------|
|   | Director      | 10% Owner | Officer        | Other |
| El-Hibri Fuad<br>2273 RESEARCH BLVD, SUITE 400<br>ROCKVILLE, MD 20850 | X             | X         | CEO & Chairman |       |

## Signatures

/s/ Carl A. Valenstein,  
attorney-in-fact

09/14/2009

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2009, as modified on August 11, 2009.

- (2) This price is the weighted average sales price for the transactions reported on this line. The prices for the transactions reported on this line range from \$19.00 to \$19.72. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

- (3) This price is the weighted average sales price for the transactions reported on this line. The prices for the transactions reported on this line range from \$19.25 to \$19.49. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

- (4) These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

- (5) Mr. El-Hibri holds, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Intervac, L.L.C. is the direct owner of 7,181,835 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,731,079 shares.

- (6) Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,965,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,191,057 shares.

- (7) Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.